Inside The FTC's Take On Generic Access To Branded Drugs

The Federal Trade Commission has spent the better part of a decade pressing an expansive view of antitrust law in the context of patent settlement agreements between branded and generic pharmaceutical...

Already a subscriber? Click here to view full article